Deferred Tax Assets, Operating Loss Carryforwards of BriaCell Therapeutics Corp. from 31 Jul 2021 to 31 Jul 2025

Taxonomy & unit: us-gaap: USD
Description: Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary: BriaCell Therapeutics Corp. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 31 Jul 2021 to 31 Jul 2025.
BriaCell Therapeutics Corp. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Jul 2025 was $8,494,300, a 53% increase year-over-year.
Source SEC data: View on sec.gov

Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)

Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

BriaCell Therapeutics Corp. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2025	$8,494,300	+$2,949,175	+53%	31 Jul 2025	10-K	16 Oct 2025	2025	FY
Q2 2024	$5,545,125	+$631,175	+13%	31 Jul 2024	10-K	16 Oct 2025	2025	FY
Q2 2023	$4,913,950	+$897,990	+22%	31 Jul 2023	10-K	29 Oct 2024	2024	FY
Q2 2022	$4,015,960	+$106,423	+2.7%	31 Jul 2022	10-K	25 Oct 2023	2023	FY
Q2 2021	$3,909,537			31 Jul 2021	10-K	28 Oct 2022	2022	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.